B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

Osi 632

0 PubMed studies analyzed

Similar Compounds by Shared Targets

The following compounds share molecular targets with Osi 632, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

cediranib
38 shared targets
lenvatinib
21 shared targets
saracatinib
26 shared targets
brivanib
21 shared targets
tivozanib
20 shared targets
vandetanib
37 shared targets
infigratinib
17 shared targets
motesanib
21 shared targets
gsk
19 shared targets
raf
25 shared targets
Loading evidence profile...

This evidence profile for Osi 632 is generated deterministically from 0 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: v20260227-01. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.